Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2016

View Archived Issues

mAbxience and UCAB to lead palivizumab biosimilar project for RSV

Umecrine Cognition raises funds to support clinical development of GR-3027

ANI to acquire Inderal LA assets from Cranford Pharmaceuticals

FDA grants orphan drug designation for PNT-2258 for the treatment of DLBCL

Sylentis reports positive phase II results for SYL-1001

DREAM silencing associated with early neuroprotection in Huntington's disease

Ritter Pharmaceuticals initiates phase IIb/III study of RP-G28

First patients dosed in Quark Pharmaceuticals' pivotal studies

Inovio Pharmaceuticals acquires Bioject's needle-free injection technology

Tesaro submits NDA for intravenous rolapitant

Imbruvica available in U.S. as first-line treatment for CLL

Japanese scientists patent E-NPP 2 inhibitors

UCL Business discloses cyclophilin D inhibitors

ViveBio and Butantan Institute collaborate to evaluate ViveST technology in dengue trial

Northwestern University reports development of APOBEC-3G expression enhancers

Taisho Pharmaceutical presents antibacterial agents

FDA accepts Aeglea's IND for AEB-1102 for hematological malignancies

Eli Lilly develops novel EP4 receptor antagonists

Celator's phase III trial of Vyxeos for high-risk AML meets primary endpoint

Epidiolex treatment leads to significant reduction in convulsive seizures in phase III pivotal trial

FDA grants priority review to atezolizumab BLA for advanced bladder cancer

Navidea Biopharmaceuticals and Platinum sign agreement reaffirming loan obligations

miR-26b may be useful as a prognostic biomarker in advanced breast cancer

BioInvent and Oncurious partner with research consortium for phase I/IIa study of TB-403

Takeda and Frazier Healthcare launch Outpost Medicine

Lower TSPO expression may be a marker of poor prognosis in ACC

Dacomitinib evaluated in advanced or metastatic PSCC chemonaive patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...